About Dr. Huang Gang
Dr. Huang Gang (黄钒) is a Professor, Doctoral Supervisor, and one of China's foremost authorities in nuclear medicine and molecular imaging, based at the Department of Nuclear Medicine, Changhai Hospital, Naval Medical University (Second Military Medical University). Recognized nationally and internationally as a leading expert in PET-CT, PET-MRI, and theranostics — the integration of diagnostic molecular imaging with targeted radionuclide therapy — Dr. Huang has established himself as one of China's most accomplished nuclear medicine physicians, with a research and clinical practice that has shaped the development and standardization of molecular imaging and radionuclide therapy across China.
Nuclear medicine and molecular imaging have been transformed over the past decade by the development of novel PET tracers beyond FDG — including PSMA-PET for prostate cancer, DOTATATE-PET for neuroendocrine tumors, amyloid and tau PET for neurodegenerative disease, and fibroblast activation protein inhibitor (FAPI) PET for a broad range of solid tumors — and by the emergence of theranostics as a powerful treatment paradigm in which the same molecular target used for diagnostic imaging is exploited for targeted radionuclide therapy. Lutetium-177 PSMA therapy for metastatic castration-resistant prostate cancer and lutetium-177 DOTATATE therapy for progressive neuroendocrine tumors represent the most established examples of this approach, with randomized trial evidence demonstrating meaningful improvements in progression-free and overall survival. Dr. Huang's expertise spans the full spectrum of modern nuclear medicine — from conventional bone scintigraphy and thyroid imaging through advanced PET-CT and PET-MRI with novel tracers to theranostic radionuclide therapy — making him a uniquely valuable resource for international patients with oncological and non-oncological conditions requiring molecular imaging assessment or radionuclide therapy.
Hospital Affiliation: Department of Nuclear Medicine, Changhai Hospital
Changhai Hospital (长海医霂), affiliated with Naval Medical University, is one of Shanghai's largest and most prestigious academic medical centers. Its Department of Nuclear Medicine is one of the highest-volume and most technologically advanced nuclear medicine departments in China, equipped with the latest generation of molecular imaging platforms: digital PET-CT systems with time-of-flight (TOF) capability for high-sensitivity, high-resolution whole-body PET imaging; PET-MRI for simultaneous PET and MRI acquisition enabling superior soft tissue characterization combined with metabolic imaging; SPECT-CT systems for conventional nuclear medicine studies; and a dedicated radiopharmacy for the preparation of FDG and novel PET tracers including PSMA ligands, DOTATATE, FAPI, and other investigational tracers.
The department's theranostics program — one of the most active in China — provides lutetium-177 PSMA therapy for metastatic castration-resistant prostate cancer, lutetium-177 DOTATATE therapy for progressive neuroendocrine tumors, radioiodine (I-131) therapy for differentiated thyroid cancer and hyperthyroidism, and other radionuclide therapies in a dedicated radiation therapy suite with appropriate radiation protection infrastructure. The department maintains active research collaborations with nuclear medicine centers across China and internationally, and participates in national and international clinical trials of novel PET tracers and theranostic agents.
Clinical Specialties: What Dr. Huang Gang Provides
- FDG PET-CT for oncological staging and restaging — whole-body FDG PET-CT for initial staging, restaging after treatment, and detection of recurrence across all major solid tumor types including lung cancer, lymphoma, colorectal cancer, esophageal cancer, head and neck cancer, cervical cancer, and melanoma; assessment of treatment response using PERCIST criteria; detection of unknown primary tumor; evaluation of solitary pulmonary nodules; FDG PET-CT-guided biopsy site selection for heterogeneous tumors
- PSMA PET-CT for prostate cancer — Ga-68 PSMA PET-CT and F-18 PSMA PET-CT for biochemical recurrence after radical prostatectomy or radiotherapy; initial staging of high-risk prostate cancer; assessment of metastatic castration-resistant prostate cancer (mCRPC) for lutetium-177 PSMA therapy eligibility; response assessment after PSMA-targeted therapy; superior sensitivity and specificity compared to conventional CT and bone scintigraphy for prostate cancer staging and restaging
- DOTATATE PET-CT for neuroendocrine tumors — Ga-68 DOTATATE PET-CT for staging, restaging, and somatostatin receptor expression assessment in gastroenteropancreatic neuroendocrine tumors (GEP-NETs), bronchial carcinoids, pheochromocytoma, paraganglioma, and other somatostatin receptor-expressing tumors; eligibility assessment for lutetium-177 DOTATATE (PRRT) therapy; response assessment after PRRT
- FAPI PET-CT — F-18 or Ga-68 FAPI PET-CT for staging of solid tumors with low FDG avidity including gastric cancer, pancreatic cancer, cholangiocarcinoma, and peritoneal metastases; superior tumor-to-background ratio compared to FDG PET for selected tumor types; assessment of tumor-associated fibroblast activation as a therapeutic target
- Lutetium-177 PSMA therapy (Lu-177 PSMA) — patient selection and eligibility assessment for Lu-177 PSMA therapy in mCRPC based on PSMA PET-CT expression and FDG PET-CT; treatment planning and dosimetry; Lu-177 PSMA administration and post-therapy imaging; response assessment and retreatment planning; coordination with medical oncology for integration with systemic therapy
- Lutetium-177 DOTATATE therapy (PRRT) — patient selection for peptide receptor radionuclide therapy (PRRT) in progressive, somatostatin receptor-positive NETs; treatment planning and kidney dosimetry; Lu-177 DOTATATE administration and post-therapy imaging; response assessment and retreatment; coordination with gastroenterology and oncology for integration with somatostatin analogues and other systemic therapies
- Radioiodine (I-131) therapy — I-131 therapy for differentiated thyroid cancer (papillary and follicular) after thyroidectomy; ablation of thyroid remnant and treatment of metastatic disease; I-131 therapy for hyperthyroidism (Graves' disease and toxic nodular goiter); post-therapy whole-body scan; thyroglobulin monitoring and response assessment
- Bone scintigraphy and conventional nuclear medicine — Tc-99m bone scintigraphy for detection of bone metastases and benign bone disease; SPECT-CT for improved lesion localization and characterization; myocardial perfusion imaging (MPI) for coronary artery disease assessment; renal scintigraphy for differential renal function and obstruction assessment; sentinel lymph node mapping for breast cancer and melanoma
- Amyloid and tau PET for neurodegenerative disease — amyloid PET (F-18 florbetapir, florbetaben, or flutemetamol) for detection of amyloid pathology in patients with cognitive impairment; tau PET for Alzheimer's disease staging and differentiation from other tauopathies; coordination with neurology for integration of PET findings into dementia diagnosis and management
Why International Patients Choose Dr. Huang Gang and Changhai Hospital
International patients seek nuclear medicine and molecular imaging services from Dr. Huang Gang and Changhai Hospital for reasons that reflect both the technical breadth of the department's imaging capabilities and the availability of theranostic treatments — particularly Lu-177 PSMA therapy and PRRT — that may not be accessible or affordable in their home countries.
For patients with prostate cancer biochemical recurrence after radical prostatectomy or radiotherapy, PSMA PET-CT at Changhai Hospital provides a level of sensitivity for disease localization that far exceeds conventional CT and bone scintigraphy — detecting recurrent disease in up to 70–80% of patients with PSA values below 1 ng/mL where conventional imaging is negative. The identification of the site and extent of recurrence by PSMA PET-CT directly guides salvage treatment decisions, enabling targeted salvage radiotherapy or systemic therapy that would not be possible without precise disease localization.
For patients with metastatic castration-resistant prostate cancer who are PSMA PET-CT positive and FDG PET-CT negative — the eligibility criteria for Lu-177 PSMA therapy based on the VISION trial — Changhai Hospital's theranostics program provides access to this proven treatment at costs substantially below those in Western healthcare systems, where Lu-177 PSMA therapy may cost tens of thousands of dollars per cycle and may not be covered by insurance for all eligible patients.
For patients with progressive neuroendocrine tumors expressing somatostatin receptors on DOTATATE PET-CT, PRRT with Lu-177 DOTATATE at Changhai Hospital provides access to a treatment with proven efficacy in the NETTER-1 trial at costs substantially below those in Western healthcare systems. Access to PSMA PET-CT, DOTATATE PET-CT, FAPI PET-CT, and theranostic treatments at Changhai Hospital can typically be arranged within days through CMCS.
What to Expect at Your Consultation
Nuclear medicine consultations arranged through CMCS at Changhai Hospital begin with a review of all prior imaging — including CT, MRI, prior PET-CT reports and images, and bone scintigraphy — relevant laboratory investigations (PSA for prostate cancer, chromogranin A and 5-HIAA for NETs, thyroglobulin for thyroid cancer, tumor markers), prior pathology and molecular profiling results, and the patient's oncological history and current treatment status. CMCS will arrange certified translation of all medical records and imaging reports in advance of the consultation. Dr. Huang will assess the clinical indication for molecular imaging or radionuclide therapy, select the optimal imaging protocol or treatment approach, and coordinate the imaging study or therapy administration. A written English-language nuclear medicine report is provided after every study, and CMCS will facilitate direct communication between Dr. Huang's team and the patient's home oncologist for integration of the findings into the overall treatment plan.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides comprehensive end-to-end support for international patients seeking nuclear medicine and molecular imaging services with Dr. Huang Gang at Changhai Hospital. Our services include priority scheduling of PET-CT, PET-MRI, and radionuclide therapy, certified translation of prior imaging reports and medical records, coordination of pre-imaging and pre-therapy investigations, on-site interpretation throughout the consultation and procedure, post-therapy monitoring and discharge coordination, and written English-language imaging reports and therapy summaries. CMCS will also facilitate direct communication between Dr. Huang's team and the patient's home oncologist to ensure seamless integration of the Changhai Hospital nuclear medicine assessment into the patient's overall care plan.
📧 contract@medicalsh.com | 💬 WeChat: gezhanglao | 🌐 medicalsh.com
댓글 0개